<DOC>
	<DOCNO>NCT02269735</DOCNO>
	<brief_summary>The purpose Part I study evaluate safety tolerability intravenous ( IV ) dose MK-2640 healthy participant obtain preliminary plasma pharmacokinetic profile MK-2640 . The purpose Parts II III study evaluate safety tolerability IV dose MK-2640 regular human insulin ( RHI ) , evaluate pharmacokinetic pharmacodynamic profile MK-2640 RHI participant type 1 diabetes mellitus ( T1DM ) . Part II initiate Part I general safety , tolerability observe data supportive progression Part II . Part III initiate Parts I II general safety , tolerability observe data supportive progression Part III .</brief_summary>
	<brief_title>A Three-part Study Evaluate Safety , Pharmacokinetics Pharmacodynamics MK-2640 Healthy Participants ( Part I ) Participants With Type 1 Diabetes Mellitus ( Parts II III ) ( MK-2640-001 )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<criteria>Inclusion Criteria ( Part I ) : healthy male healthy female nonchild bear potential good health nonsmoker and/or use nicotine nicotinecontaining product ( e.g. , nicotine patch ) least approximately 3 month Inclusion Criteria ( Parts II III ) : male female nonchild bear potential T1DM least 12 month stable dos insulin good health nonsmoker and/or use nicotine nicotinecontaining product ( e.g. , nicotine patch ) least approximately 3 month mentally legally incapacitate , significant emotional problem time screen visit expect conduct trial history clinically significant psychiatric disorder last 5 year history clinically significant endocrine ( except T1DM Part II subject ) , gastrointestinal , cardiovascular , hematological , hepatic , immunological , renal , respiratory , genitourinary major neurological ( include stroke chronic seizure ) abnormality diseases positive hepatitis B surface antigen , hepatitis C antibodies human immunodeficiency virus ( HIV ) history cancer ( malignancy ) , except adequately treat nonmelanomatous skin carcinoma carcinoma situ cervix history significant multiple and/or severe allergy , anaphylactic reaction significant intolerability prescription nonprescription drug food , major surgery , donate lose 1 unit blood within 4 week prior screen visit participate another investigational trial within 4 week prior screen visit unable refrain anticipates use medication , include prescription nonprescription drug herbal remedy begin approximately 2 week prior administration initial dose trial drug , throughout trial , posttrial visit consumes great 3 glass alcoholic beverage daily consumes great 6 serving coffee , tea , cola , energydrinks , caffeinated beverage per day . currently regular recreational user cannabis , illicit drug history drug ( include alcohol ) abuse within approximately 3 month Exclusion Criteria ( Parts II III ) : history diabetic ketoacidosis last 6 month . one severe hypoglycemic episode associate hypoglycemic seizure , coma unconsciousness within 2 week prior dose use systemic ( intravenous , oral , inhale ) glucocorticoid within 3 month screen anticipated require treatment systemic glucocorticoid study participation history hypersensitivity pharmacologic insulin inactive ingredient regular human insulin , E. coliderived drug product</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>